Hims & Hers Health expands into menopause and perimenopause care with personalized, affordable treatment plans for women. The program connects users to licensed providers trained in women’s health, addressing symptoms like hot flashes and sleep issues while improving access to quality care.

Hims & Hers closed Q2 2025 with $544.8M in revenue up 73% year-over-year net income of $42.5M, and 2.44M subscribers. The company reaffirmed its full-year outlook.

Hims & Hers enters Canadian market with a digital weight loss program leveraging generic semaglutide, signaling increased competition and accessibility in the growing GLP-1 and obesity treatment sector.

Novo Nordisk has ended its collaboration with Hims & Hers, citing concerns over compounded versions of Wegovy®. The decision follows scrutiny around patient safety and regulatory compliance in the telehealth weight loss space.